Bros. Advisors Lp Baker Acquires 30,874 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) major shareholder Bros. Advisors Lp Baker bought 30,874 shares of the firm’s stock in a transaction on Monday, November 10th. The stock was acquired at an average price of $7.21 per share, for a total transaction of $222,601.54. Following the transaction, the insider owned 4,529,969 shares of the company’s stock, valued at approximately $32,661,076.49. The trade was a 0.69% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Bros. Advisors Lp Baker also recently made the following trade(s):

• On Wednesday, November 12th, Bros. Advisors Lp Baker bought 100,736 shares of Entrada Therapeutics stock. The stock was bought at an average cost of $7.76 per share, with a total value of $781,711.36.
• On Tuesday, November 11th, Bros. Advisors Lp Baker purchased 46,434 shares of Entrada Therapeutics stock. The shares were bought at an average cost of $7.50 per share, for a total transaction of $348,255.00.

Entrada Therapeutics Price Performance

TRDA stock opened at $8.78 on Friday. The stock has a market cap of $335.57 million, a price-to-earnings ratio of -3.53 and a beta of -0.08. The company has a 50 day simple moving average of $6.17 and a 200 day simple moving average of $6.70. Entrada Therapeutics, Inc. has a 1 year low of $4.93 and a 1 year high of $21.79.

Entrada Therapeutics (NASDAQ:TRDA) last issued its earnings results on Thursday, November 6th. The company reported ($1.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.04) by ($0.02). The company had revenue of $1.61 million during the quarter, compared to analyst estimates of $8.62 million. Entrada Therapeutics had a negative net margin of 168.16% and a negative return on equity of 26.42%. On average, equities research analysts anticipate that Entrada Therapeutics, Inc. will post 1.12 EPS for the current fiscal year.

Institutional Investors Weigh In On Entrada Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in TRDA. Merck & Co. Inc. acquired a new position in shares of Entrada Therapeutics in the first quarter worth approximately $15,728,000. Wellington Management Group LLP raised its holdings in Entrada Therapeutics by 2.1% during the 1st quarter. Wellington Management Group LLP now owns 1,053,314 shares of the company’s stock worth $9,522,000 after purchasing an additional 21,488 shares during the last quarter. Geode Capital Management LLC raised its holdings in Entrada Therapeutics by 7.2% during the 2nd quarter. Geode Capital Management LLC now owns 631,554 shares of the company’s stock worth $4,245,000 after purchasing an additional 42,479 shares during the last quarter. Royce & Associates LP lifted its position in shares of Entrada Therapeutics by 54.8% in the 3rd quarter. Royce & Associates LP now owns 345,507 shares of the company’s stock worth $2,004,000 after purchasing an additional 122,256 shares during the period. Finally, BNP Paribas Financial Markets boosted its stake in shares of Entrada Therapeutics by 4,767.4% in the 3rd quarter. BNP Paribas Financial Markets now owns 148,212 shares of the company’s stock valued at $860,000 after purchasing an additional 145,167 shares during the last quarter. Institutional investors and hedge funds own 86.39% of the company’s stock.

Analysts Set New Price Targets

TRDA has been the topic of a number of research reports. Wall Street Zen lowered Entrada Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 9th. Roth Capital set a $13.00 price target on Entrada Therapeutics in a report on Thursday, November 6th. Zacks Research raised Entrada Therapeutics to a “hold” rating in a research note on Friday, August 8th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Entrada Therapeutics in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $20.67.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.